Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients

被引：0
|
作者：
Umland, Tim [1 ]
Hintz, Andreas [1 ]
Niess, Gero [2 ]
Guendogdu, Mehtap [2 ]
Tacke, Frank [3 ]
机构：
[1] Alexander Apotheke, Hamburg, Germany
[2] Gilead Sci GmbH, Planegg, Germany
[3] Charite Campus Mitte, Med Klin MS Hepatol & Gastroenterol, Berlin, Germany
来源：
JOURNAL OF HEPATOLOGY | 2021年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PO-377
引用
收藏
页码：S793 / S793
页数：1
相关论文
共 50 条
  • [31] A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone
    Bonnet, C.
    Thomas-Schoemann, A.
    Boudou-Rouquette, P.
    Huillard, O.
    Carton, E.
    Cessot, A.
    Morin, B.
    Giroux, J.
    Tlemsani, C.
    Arrondeau, J.
    Vidal, M.
    Blanchet, B.
    Alexandre, J.
    Goldwasser, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S193 - S193
  • [32] Patients' Use and Perceptions of a Drug-Drug Interaction Database: A Survey of Janusmed Interactions
    Justad, Hanna
    Askfors, Ylva
    Shemeikka, Tero
    Andersson, Marine L.
    Hammar, Tora
    PHARMACY, 2021, 9 (01)
  • [33] Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer.
    Lee, Esther K.
    Jamani, Rehana
    Berry, Scott R.
    DeAngelis, Carlo
    Giotis, Angie
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [34] Determination of drug-drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen
    Mahfouz, Mona
    Alkhalid, Zaid Nabeel
    Birand, Nevzat
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 830 - 843
  • [35] Risk Factors for Potential Drug-Drug Interactions in Patients on Chronic Peritoneal Dialysis
    Stojadinovic, Milorad
    Lausevic, Mirjana
    Milosevic, Iman Assi
    Zaric, Radica Zivkovic
    Jemcov, Tamara Kosta
    Komadina, Ljiljana
    Petrovic, Dejan Slavko
    Djuric, Petar
    Bulatovic, Ana
    Jakovljevic, Stefan
    Jankovic, Slobodan
    PHARMACOLOGY, 2024, 109 (03) : 147 - 155
  • [36] Drug polypharmacy patterns in geriatric patients receiving chemotherapy: Implications for drug-drug interactions and adverse events.
    Sokol, K
    Krasnow, R
    Knudsen, J
    Cantilena, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1087 - 1087
  • [37] 3Risk factors for potential drug-drug interactions in patients with pneumonia
    Jankovic, Slobodan
    Zaric, Radica Zivkovic
    Stojadinovic, Milorad
    Lazic, Zorica
    Cekerevac, Ivan
    Susa, Romana
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (01) : 42 - 46
  • [38] Risk factors for potential drug-drug interactions in intensive care unit patients
    Jankovic, Slobodan M.
    Pejcic, Ana V.
    Milosavljevic, Milos N.
    Opancina, Valentina D.
    Pesic, Nikola V.
    Nedeljkovic, Tamara T.
    Babic, Goran M.
    JOURNAL OF CRITICAL CARE, 2018, 43 : 1 - 6
  • [39] Drug-drug interactions in medical patients:: Effects of in-hospital treatment and relation to multiple drug use
    Köhler, GI
    Bode-Böger, SM
    Busse, R
    Hoopmann, M
    Welte, T
    Böger, RH
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (11) : 504 - 513
  • [40] RISK OF MULTIPLE DRUG INTERACTIONS POTENTIALLY LINKED TO SAFETY IN PATIENTS RECEIVING PANGENOTYPIC DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C
    Turnes, Juan
    Garcia-Herola, Antonio
    Morillo, Ramon
    Mendez, Marinela
    Rueda, Magdalena
    Hernandez, Candido
    Sicras-Mainar, Antoni
    GUT, 2022, 71 : A97 - A98
12345